Compare RGP & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | MXCT |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.8M | 160.0M |
| IPO Year | 2000 | 2021 |
| Metric | RGP | MXCT |
|---|---|---|
| Price | $3.77 | $0.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.00 | ★ $7.50 |
| AVG Volume (30 Days) | 463.9K | ★ 1.5M |
| Earning Date | 04-06-2026 | 04-06-2026 |
| Dividend Yield | ★ 7.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $551,331,000.00 | $38,627,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.49 | $9.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $0.64 |
| 52 Week High | $7.41 | $3.58 |
| Indicator | RGP | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 35.44 |
| Support Level | N/A | $0.75 |
| Resistance Level | $4.86 | $1.79 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 36.41 | 67.96 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.